ETON · Eton Pharmaceuticals

The thesis

Eton Pharmaceuticals is modestly more likely than not to beat the S&P 500 over the next three months. Third-quarter revenue of $57.9 million, up 158% from a year earlier, lifted the 2026 revenue guide to more than $175 million on 5 November 2026. The fourth-quarter report, expected around mid-March 2027, settles the case. It will show whether HEMANGEOL demand recurs or whether relaunch stocking lifted the third quarter. The Jefferies presentation on 16 November 2026 is the first chance for management to separate the two.

The rating is Medium. The operating case strengthened with the 5 November 2026 report, and three brokers raised their targets in the following week. Against that, the shares now price a high growth rate, and directors and officers have sold stock after option exercises throughout the rise. The shares closed at $63.93 on 13 November 2026, up from $61.45 the session before and 9.5% below the $70.64 intraday 52-week high of 11 November 2026.

The price already reflects much of the raised outlook. At the 13 November 2026 close, with filed figures to 5 November 2026, the shares trade at 37.0 times earnings and 12.8 times sales. Those earnings include a one-time tax benefit.

Bullish and bearish views on Eton Pharmaceuticals, Inc.

The bull case on Eton Pharmaceuticals, Inc. (ETON), in brief: revenue beat by a wide margin. The bear case: one relaunched product drives the jump.

Bull case

• Revenue beat by a wide margin. Third-quarter revenue of $57.9 million compares with $22.5 million a year earlier and with the $41.985 million analyst estimate reported by Benzinga on 5 November 2026. The company said it passed its $200 million annualized revenue goal five quarters ahead of schedule.
• Guidance rose on both lines. On 5 November 2026 Eton raised 2026 revenue guidance to more than $175 million from more than $145 million. It also lifted the floor for its adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) margin to at least 40% from at least 35% (Form 8-K).
• Margins widened quarter after quarter. Filed gross margin rose to 76.5% in the quarter to 30 September 2026 from 35.0% a year earlier. Operating margin rose to 39.7% from −6.1% over the same span (Form 10-Q, filed 5 November 2026). Adjusted EBITDA was $28.5 million, or 49% of revenue.
• Cash roughly doubled in a quarter. Cash was $55.6 million at 30 September 2026, up from $26.8 million at 30 June 2026, against debt of about $23.1 million (Form 10-Q). Operating cash flow over the four quarters to 30 September 2026 was $38 million. No equity offering has been announced since the report.
• Brokers raised targets after the report. Canaccord Genuity raised its target to $80 from $68 and HC Wainwright set $80 on 6 November 2026. B. Riley kept its Buy rating and raised its target to $81 from $70 on 10 November 2026.
• The pipeline carries dated milestones. The FDA decision date for LIBERVANT in ages 6 to 11 is 29 March 2027, and for the KHINDIVI under-five label it is 28 May 2027 (Form 8-K, 5 November 2026). On 5 November 2026 Eton reported that its ET-700 zinc acetate formulation for Wilson disease showed fewer drug-related adverse events than GALZIN in a pilot study, with no serious adverse events. On 2 November 2026 it licensed ET-900, a mecasermin (IGF-1) program for infantile spasms, with Phase 2 first dosing targeted for the first quarter of 2027.

Bear case

• One relaunched product drives the jump. Eton attributed growth mainly to HEMANGEOL in its first full quarter after the 1 May 2026 relaunch. The 5 November 2026 release gave no per-product revenue and no figure for initial stocking.
• Net income was flattered by a tax item. GAAP net income of $35.2 million, or $1.06 per diluted share, included a $12.9 million release of a deferred-tax valuation allowance (Form 8-K, 5 November 2026). Pre-tax income was $22 million, and adjusted earnings were $0.50 per share, so the 37.0 earnings multiple rests partly on a one-time gain.
• Insiders keep selling into strength. Director Charles J. Casamento exercised options on 80,555 shares and sold all of them at an average $66.35 on 10 November 2026. Chief commercial officer Ipek Erdogan-Trinkaus exercised and sold 3,500 shares at an average $67.41 the same day (SEC Form 4 filings of 10 November 2026 and 12 November 2026). Chief executive Sean Brynjelsen sold 100,000 shares at an average $60.88 on 19 August 2026 and 20 August 2026, and director Paul V. Maier sold 50,000 at an average $59.07 on 28 August 2026 (SEC Form 4).
• Share count keeps rising. The diluted share count rose 23.7% from a year earlier in the quarter to 30 September 2026, and shares outstanding reached 28,827,905 at that date from 27,047,061 at 31 December 2025 (Form 10-Q). New licences such as LIBERVANT, ASN-001 and ET-900 add costs ahead of revenue.
• Sales run through one distributor. AnovoRx accounted for 93.8% of nine-month product revenue (Form 10-Q, period ended 30 September 2026), so any disruption there would hit reported revenue directly.
• Shared economics on IMPAVIDO. A 19 May 2026 Form 8-K requires payments to the supplier of 55% of annual net sales up to $7 million and 50% above it.

Price setup

The shares closed at $56.46 on 6 November 2026, the first session after the third-quarter report. They then closed at $64.35 on 9 November 2026, $67.54 on 10 November 2026 and $68.40 on 11 November 2026, when they touched the intraday 52-week high of $70.64. They fell to $61.45 on 12 November 2026, a day with no company news other than the Form 4 for the chief commercial officer's sale, and closed at $63.93 on 13 November 2026.

The 13 November 2026 close sits above the 50-day moving average of $55.26 and well above the 200-day moving average of $37.86, both as of that date. The three-month change is 3.6%, measured from the 17 August 2026 close of $61.73: the shares traded near current levels in August before the report, fell back, and re-rated on the results. The 52-week closing low was $14.35 on 5 February 2026.

The case turns on two levels. The $70.64 high of 11 November 2026 is the level a renewed rise has to clear. The 50-day average and the $56.46 close of 6 November 2026 mark where the shares traded just after the guidance raise; a return below them would show the market giving back the re-rating. Trading volume is limited for a company of this size, so percentage moves can overstate what changes hands at those prices.

Catalysts ahead

• 16 November 2026: Eton presents at the Jefferies Global Healthcare Conference in London, 10:00 to 10:25 a.m. Eastern, by webcast. Management may say how much of third-quarter HEMANGEOL revenue was initial stocking and how the more-than-$175 million 2026 guide splits across products.
• ~31 December 2026 (est.): Glyburide oral suspension NDA submission, targeted for late 2026 or early 2027. A filing would advance a Fast Track pipeline product toward a further revenue line.
• ~15 March 2027 (est.): Fourth-quarter and full-year 2026 results, with 2027 guidance. Fourth-quarter product revenue against the third quarter's $57.9 million shows whether HEMANGEOL demand recurs; 2027 guidance shows whether the 40%-plus adjusted EBITDA margin holds.
• 29 March 2027: FDA decision date for LIBERVANT, ages 6 to 11. Approval gates the planned April 2027 launch and triggers a $2.5 million milestone; a complete response letter would delay a new revenue line.

What would change the view

A daily close below $50.00, under the 50-day average and the $56.46 close of 6 November 2026, which would show the market giving back the re-rating after the third-quarter report. Quarterly product revenue below $50 million, or a cut to the more-than-$175 million 2026 revenue guide, would also break the case.

The risks this note tracks, each with what would confirm it:

• HEMANGEOL relaunch stocking inflated the third quarter, making $57.9 million an unreliable run-rate. Confirmed by: quarterly product revenue below $50 million, a sequential decline management attributes to HEMANGEOL demand, or management quantifying initial stocking at the 16 November 2026 Jefferies presentation.
• Growth fails to sustain the raised outlook into 2027. Confirmed by: a cut to the more-than-$175 million 2026 revenue guide, or 2027 guidance with revenue below about $230 million or an adjusted EBITDA margin below 40%.
• Deal cadence leads to equity issuance and further dilution. Confirmed by: a registered offering or at-the-market program filing after the 5 November 2026 report.
• Distributor concentration: AnovoRx handled 93.8% of nine-month product revenue. Confirmed by: a disclosed disruption, termination or dispute at AnovoRx in an 8-K or the fourth-quarter report.
• LIBERVANT approval slips, delaying the April 2027 launch. Confirmed by: a complete response letter at the 29 March 2027 FDA action date.
• Continued insider selling signals management sees the price as full. Confirmed by: further Form 4 open-market sales by the chief executive or directors after the 10 November 2026 sales by director Charles J. Casamento and the chief commercial officer.

What it trades with

The November moves were company-specific. The rise from 6 November to 11 November 2026 followed the third-quarter report and three target raises, and the 12 November 2026 decline came alongside insider-sale filings with no other company news. Revenue comes from marketed rare-disease and pediatric products such as HEMANGEOL, KHINDIVI, INCRELEX and IMPAVIDO, so results depend less on trial readouts than at most small-cap biotechs. A common market view is that small-cap health-care shares move with sector funding sentiment; for Eton that link runs through deal funding, since past licences and acquisitions have been paid for partly with new shares.